MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ
3.430
+0.020
+0.59%
Opening 12:00 01/06 EST
OPEN
3.390
PREV CLOSE
3.410
HIGH
3.450
LOW
3.350
VOLUME
245.77K
TURNOVER
--
52 WEEK HIGH
4.020
52 WEEK LOW
2.455
MARKET CAP
267.97M
P/E (TTM)
-1.9323
1D
5D
1M
3M
1Y
5Y
1D
Atea Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Reuters · 11h ago
Weekly Report: what happened at AVIR last week (1229-0102)?
Weekly Report · 1d ago
Weekly Report: what happened at AVIR last week (1222-1226)?
Weekly Report · 12/29/2025 10:07
Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026
Seeking Alpha · 12/23/2025 10:51
Atea Completes Enrollment In C-BEYOND Hepatitis C Trial; Data Due In Mid-2026
NASDAQ · 12/23/2025 07:19
Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial
TipRanks · 12/22/2025 12:06
Atea Pharmaceuticals Completes Enrollment Of Over 880 Treatment-naïve Patients In C-BEYOND Phase 3 Trial Of Fixed-dose Combination Bemnifosbuvir And Ruzasvir Compared To Sofosbuvir And Velpatasvir Regime For Hepatitis C Virus; Results Are Expected Mid-year 2026
Benzinga · 12/22/2025 12:05
Atea Pharmaceuticals Completes Enrollment in Phase 3 HCV Trial of Bemnifosbuvir and Ruzasvir
Reuters · 12/22/2025 12:00
More
About AVIR
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The Company has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.

Webull offers Atea Pharmaceuticals Inc stock information, including NASDAQ: AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.